Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 49

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 49
---
) until 
 30 days after the effective date of the Registration Statement; and                           |

| ● | We                                                                                          
 agreed to seek stockholder approval in accordance with the applicable rules and regulations 
 of Nasdaq (“Stockholder Approval”) of, and to solicit our stockholders’                     
 affirmative vote for approval of, the issuance of the Warrant Shares at our Annual Meeting, 
 and, if Stockholder Approval is not obtained at the Annual Meeting, to call a meeting every 
 90 days thereafter to seek such Stockholder Approval until the earlier of the date on which 
 Stockholder Approval is obtained or the Warrants are no longer outstanding. This Issuance   
 Proposal is intended to fulfill this final covenant.                                        |

The Engagement Letter

Pursuant to the Engagement Letter, we paid Wainwright a total cash fee equal to 7.0% of the aggregate gross proceeds of the Private Placement, as well as certain expenses, and Brookline received up to 15% of the cash fee. In addition, the Company issued to Wainwright, or its designees, the Placement Agent Warrants to purchase up to an aggregate of 361,111 shares of common stock at an exercise price equal to $0.5625 per share.

The Common Warrants

The Common Warrants are exercisable on or after Stockholder Approval until the three-year anniversary of the Stockholder Approval. The Common Warrants have an exercise price of $0.45 per share. The exercise price and number of shares issuable upon exercise of the Common Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the common stock and the exercise price. Upon any such price-based adjustment to the exercise price, the number of shares issuable upon exercise of the Common Warrants will be adjusted proportionately. The Common Warrants may be exercised for cash, provided that, if there is no effective registration statement available registering resale of the Common Warrant Shares, the Common Warrants may be exercised on a cashless basis. The Placement Agent Warrants have substantially the same terms as the Common Warrants.

Effect of the Issuance of the Common Stock Underlying the Pre-Funded Warrants and Warrants

The potential issuance of the shares of common stock underlying the Pre-Funded Warrants and Warrants would result in an increase in the number of shares of common stock outstanding, and our stockholders would incur dilution of their percentage ownership to the